Jisella Dolan

Jisella Dolan is a global leader in aging, caregiving, and longevity with more than twenty years experience scaling home care, aging in place, workforce, healthcare, and the legal field. She has been recognized for her vision and expertise by many organizations, including receiving the United Nations and World Health Organization’s “Healthy Ageing 50 Award” as one of the top fifty leaders transforming aging around the globe. She was also selected by The Holding Co. and Pivotal Ventures for The Care Guild, which honors twenty-five influential leaders who are reimagining care in America.

For sixteen years, Ms. Dolan led Home Instead + Honor Technology to be the world’s largest provider of home care services that empower people to age in place, with more than 1,200 locations around the globe, more than $2.5B in annual revenue, and more than 100 million hours of care delivered yearly. Home Instead + Honor revolutionized care for older adults through the unique marriage of high-tech and high-touch.

She served on Home Instead’s Executive Team and led the Advocacy division, which advocates for aging adults and their families, ensures a quality care experience globally, transforms healthcare delivery, and shapes aging and home care policy around the world. She also led Honor’s social purpose work.

During her career, Ms. Dolan has advanced movements nationally and globally to reimagine care, aging, family caregiving, workforce, and women’s leadership. Through this work, she has served in a number of leadership roles, including as Strategy Officer for the World Economic Forum; Board of Directors for Home Care Association of America; and member of the federal RAISE Act Family Caregiving Advisory Council, the Women’s Leadership Council for Women Against Alzheimer’s, Fortune’s Most Powerful Women community, G100 Next Gen, and Chief. She was recently selected to join the prestigious Global Coalition on Aging’s Advisory Council to advance innovative solutions and policy change to empower aging and caregiving. Before joining Home Instead, she was partner at a global law firm.

Today Ms. Dolan is a passionate advocate in building a better future for family caregivers, older adults, women leaders, and workforce. She provides consulting and advisory services to a variety of organizations who are advancing solutions to make the world a better place for all. The challenges family caregivers face hit home for Jisella, as she is a mom to her daughter, while providing caregiving support to her late father, her late stepfather who suffered from dementia, and now her mother.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.